WuXi TIDES has a dedicated analytical team with extensive experience and expertise in oligonucleotide analysis across all development phases from pre-clinical development to commercial manufacturing, covering both drug substance and drug product.

Equipped with state-of-the-art instruments and co-located with the API process development team, our oligonucleotide analytical service streamlines your oligonucleotide development process with a customized, flexible, and integrated analytical solution.

Analytical Development

Drug Substance Specific Analytical Services

Drug Product Specific Analytical Services

Quality Control

Special Capabilities

Key Equipment

Case Study 1: Purity and Impurities by LC-UV-HRMS (tRNA/gRNA)

For the impurites that are hard to be separated from or co-eluting with FLP in HPLC-UV, MS purity is utilized for the qualificaiton and quantitation of impurities in tRNA, sgRNA PMO/PPMO and ASO analysis. 

Case Study 2: Purity and Impurities by LC-UV (sgRNA-100mer)

Evolution of resolution of HPLC purity method for sgRNA. From separation capability of n-8 and n+4 impurities initially to n-2 and n+1 impurities by current method at WuXi TIDES.

Case Study 3: Sequencing of PPMO

The determination of the Peptide-PMO sequence involves sequencing both the peptide and PMO components of the PPMO, as well as the conjugation process between the two intermediates.

Case Study 4: Systematically Screen Purity Methods for Improved Resolution

Both Ion-Exchange Chromatography (IEX) and Reverse-Phase HPLC (RP-HPLC) are utilized for the purity and impurity analysis of PMO product. These orthogonal chromatography techniques provide an accurate depiction of the product’s quality. 

  • WuXi STA has ability to screen methods systematically to get a better purity method with more resolved impurity peaks.
  • IEX purity method and RP purity method display different impurity profiles.
Scroll to Top
Please enable JavaScript in your browser to complete this form.
Checkboxes